Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0926 • ACR Convergence 2025
Discovery and Characterization of SIM0711: a Potent and Selective IRAK4 PROTAC with Improved Efficacy and Safety
Minyun Zhou¹, Peng Gu², Mengyu Wang³, Yuxi Yan², Li Sun³, Yiling Chen³, Xin Wang³, Feng Tang¹, Shunwei Zhu² and Xiaofeng Zhao⁴, ¹State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical group, Nanjing, ²State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Shanghai, China (People's Republic), ³State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ⁴State Key Laboratory of Neurology and oncolog Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic)
Background/Purpose: IRAK4 plays a pivotal role in the innate immune response by acting downstream of Toll-like receptors (TLRs) and the interleukin-1 receptor (IL-1R), with both…
Abstract Number: 0836 • ACR Convergence 2025
Growth Differentiation Factor-15 Predicts Frailty and Death in Rheumatoid Arthritis
Katherine Wysham¹, Hannah Brubeck², Aaron Baraff², Christian Lood³, Punyasha Roul⁴, Bryant England⁵, Beth Wallace⁶, Grant Cannon⁷, Gary Kunkel⁸, Ted Mikuls⁵, Patti Katz⁹, Dolores Shoback¹⁰, Jose Garcia¹¹, Ariela Orkaby¹², Joshua Baker¹³ and Tate Johnson⁵, ¹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³University of Washington, Seattle, WA, ⁴UNMC, Omaha, NE, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁷University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁸University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁹UCSF, San Rafael, CA, ¹⁰San Francisco VA Medical Center & University of California San Francisco, San Francisco, CA, ¹¹VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ¹²VA Boston Healthcare System & Division of Aging, Brigham and Women’s Hospital, Harvard Medical School & VA Geriatrics Research Education and Clinical Center, Boston, MA, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: RA is associated with premature aging and frailty. Growth differentiation factor-15 (GDF-15) is a biomarker that increases in response to cellular stress and inflammation…
Abstract Number: 0774 • ACR Convergence 2025
Longitudinal peripheral blood multi-omic profiling in at-risk individuals uncovers immune signatures and predictive models for future rheumatoid arthritis conversion
Jun Inamo¹, Aleksandra Bylinska², Miles Smith², Lauren Vanderlinden³, Christian Wright⁴, Tayte Stephens⁵, Marie Feser⁶, Christopher Striebich⁷, James O'Dell⁸, Jeffrey Sparks⁹, John Davis¹⁰, Jonathan Graf¹¹, Maureen McMahon¹², Elizabeth Solow¹³, Lindsy Forbess¹⁴, Athan Tiliakos¹⁵, David Fox¹⁶, Maria I. Danila¹⁷, Diane Lewis. Horowitz¹⁸, Jonathan Kay¹⁹, Judith James², V. Michael Holers²⁰, Kevin Deane²¹, Joel Guthridge² and Fan Zhang²², ¹University of Colorado School of Medicine, Aurora, CO, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Colorado Anschutz Medical Campus, Monument, CO, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵University of Oklahoma Health Science Center, Oklahoma City, OK, ⁶University of Colorado Anschutz Medical Campus, Aurora, CO, ⁷University of Colorado, Aurora, CO, ⁸University of Nebraska Medical Center, Omaha, NE, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰Mayo Clinic, Rochester, MN, ¹¹UCSF, San Francisco, CA, ¹²UCLA David Geffen School of Medicine, Los Angeles, CA, ¹³UT Southwestern Medical Center, Dallas, TX, ¹⁴Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁵Emory University, Roswell, GA, ¹⁶University of Michigan, Dexter, MI, ¹⁷University of Alabama at Birmingham, Birmingham, ¹⁸Northwell Health, New Hyde Park, ¹⁹UMass Chan Medical School, Worcester, MA, ²⁰University of Colorado Anschutz Medical Campus, Aurora, ²¹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ²²The University of Colorado, Aurora, CO

Background/Purpose: Seropositive rheumatoid arthritis (RA) has an at-risk stage identifiable by elevations of antibodies to cyclic citrullinated peptide (CCP). Identifying the immunologic factors that distinguish…
Abstract Number: 0491 • ACR Convergence 2025
Association of Short Chain Fatty Acids and Diet with Disease Activity and Methotrexate Response in New Onset Rheumatoid Arthritis: A Proof of Principle Study
Kaci French¹, Luz Alvarado², Rebecca Haberman³ and Rebecca Blank³, ¹NYU Langone, New York, NY, ²NYU Langone, New York, ³NYU Langone Health, New York, NY
Background/Purpose: Diet, the gut microbiome, and gut microbial metabolites have been implicated in rheumatoid arthritis (RA) development and modulation. Seafood based-omega-3 fatty acids modulate inflammatory…
Abstract Number: 0475 • ACR Convergence 2025
Drug Discontinuation in Inflammatory Arthritis Following Mandatory Non-Medical Switching from Originator to Biosimilar in Quebec, Canada
Cristiano Moura¹, Luck Lukusa², Denis Choquette³, Gilles Boire⁴, Nathalie Carrier⁵, Autumn Neville² and Sasha Bernatsky⁶, ¹Research Institute of the McGill University Health Center, Montréal, Canada, ²Research Institute of the McGill University Health Centre, Montreal, Canada, ³Institut de Rhumatologie de Montréal, Saint-Donat-de-Montcalm, Canada, ⁴Retired, Sherbrooke, QC, Canada, ⁵Centre integré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie-CHUS), Sherbrooke, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: In April 2022, the Canadian province of Quebec introduced a mandatory non-medical switch to biosimilars for persons on bio-originators to manage healthcare costs. Our…
Abstract Number: 0459 • ACR Convergence 2025
Risk Factors for Acute Exacerbation in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease
Rinko Katsuda¹, Akiko Kitagawa¹, Masayuki Azukizawa², Musuzu Fujimori¹ and Tetsuji Kawamura³, ¹Department of Rheumatology, NHO Himeji Medical Center, Japan, Himeji, Japan, ²Department of Orthopaedic Surgery, NHO Himeji Medical Center, Japan, Himeji, Japan, ³Department of Respiratory Medicine, NHO Himeji Medical Center, Japan, Himeji, Japan
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a common and serious extra-articular manifestation of RA, contributing to ~10% of RA-related mortality. Acute exacerbation (AE)…
Abstract Number: 0442 • ACR Convergence 2025
Beyond the Joints: The Impact of Non-Articular Pain on Patient-Reported Function in a Longitudinal Real-World Early RA Cohort
Charis Meng¹, Marie-France Valois², Caci Julia³, Yvonne Lee⁴, Bindee Kuriya⁵, Gilles Boire⁶, Hugues Allard-Chamard⁷, Carol Hitchon⁸, Louis Bessette⁹, Glen Hazlewood¹⁰, Carter Thorne¹¹, Susan J. Bartlett¹², Janet Pope¹³ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²McGill University, Pointe-Claire, QC, Canada, ³Hospital for Special Surgery, New York, ⁴Northwestern University, Chicago, IL, ⁵Mount Sinai Health, Toronto, Canada, ⁶Retired, Sherbrooke, QC, Canada, ⁷Université de Sherbrooke, Sherbrooke, Canada, ⁸University of Manitoba, Winnepeg, Canada, ⁹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²McGill University, Beaconsfield, QC, Canada, ¹³University of Western Ontario, London, ON, Canada
Background/Purpose: A third of patients with early (e)RA report pain outside the joint or non-articular pain (NAP) despite RA treatment(1). NAP, both regional and widespread,…
Abstract Number: 0359 • ACR Convergence 2025
“VA is a slow-moving ship, but you can steer it”: Clinician Views on Navigating Shared Decision-Making and Anticipated Use of an RA Decision Aid
Alicia Hamblin¹, Dylan Waller², Anaïs Tuepker², Catherine Nasrallah³, Alexandra Bennett², Brooke Jespersen², Joshua Baker⁴, Madhavi Valiveti⁵, gabriela Schmajuk⁶ and Jennifer Barton², ¹UCSF, San Francisco, CA, ²Center to Improve Veteran Involvement in Care (CIVIC) and VA Portland Health Care System, Portland, OR, ³University of California San Francisco (UCSF), San Francisco, CA, ⁴Corporal Michael J. Crescenz VA Medical Center (CMCVAMC) and University of Pennsylvania, Philadelphia, PA, ⁵VAMC Wilmington, Wilmington, DE, ⁶University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Shared decision-making (SDM) is the first overarching principle of the treat-to-target guidelines for rheumatoid arthritis (RA). The quality of SDM varies widely, and its…
Abstract Number: 0191 • ACR Convergence 2025
Advanced therapy use in RA patients with moderate disease activity in a large NHS Foundation Trust in South London, UK
Aoibhinn Kelly¹, Maddalena Rupnik², Nasra Ahmed¹, Mrinalini Dey³ and Elena Nikiphorou⁴, ¹King's College Hospital NHS Foundation Trust, London, United Kingdom, ²Faculty of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ³Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ⁴King's College London, London, United Kingdom
Background/Purpose: Moderate disease in rheumatoid arthritis (RA) is defined as a 28-joint disease activity score (DAS28) of 3.2-5.1(MDAS). As per the National Institute for Health…
Abstract Number: 0096 • ACR Convergence 2025
GLUT1-Dependent Targeting and Enhanced Selectivity of a Glucose-Methotrexate Conjugate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
Sebastian Makuch¹, Jacek Polański¹ and Wojciech Tański², ¹Wrocław Medical University, Wrocław, Poland, ²Wrocław University of Science and Technology, Wrocław, Poland
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease where fibroblast-like synoviocytes (FLS) play a central role in joint inflammation and destruction. Methotrexate (MTX), a…
Abstract Number: 0076 • ACR Convergence 2025
Antibodies to malondialdehyde-acetaldehyde are associated with circulating inflammatory mediators during the preclinical stages of rheumatoid arthritis
Emma Weis¹, Harlan Sayles¹, Geoffrey Thiele¹, Samir Rachid Zaim², Tony Merriman³, Bryant England¹, Xiaojun Li², LauraKay Moss⁴, Jess Edison⁵, Marie Feser⁴, V. Michael Holers⁶, Kevin Deane⁷, Ted Mikuls¹ and Austin Wheeler¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Allen Institute for Immunology, Seattle, WA, ³University of Alabama at Birmingham, Homewood, AL, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵Uniformed Services University of the Health Sciences / National Capital Consortium- Walter Reed Bethesda, Bethesda, MD, ⁶University of Colorado, Denver, CO, ⁷University of Colorado Denver Anschutz Medical Campus, Aurora, CO
Background/Purpose: Circulating concentrations of anti-malondialdehyde-acetaldehyde (MAA) antibodies distinguish patients with RA and are detectable years prior to arthritis onset. Recent data demonstrate that anti-MAA antibodies…
Abstract Number: 0055 • ACR Convergence 2025
TCR Signaling Thresholds Govern Anergy and Tolerance in ZAP70 Hypomorphic Models of Autoimmune Arthritis
Yuka Nakao, Astha Patel, Letitia Yang, Steven yu, Arthur Weiss and Judith Ashouri, University of California, San Francisco, San Francisco, CA
Background/Purpose: T cell receptor (TCR) signaling strength is a key determinant of immune tolerance and autoimmunity, yet the threshold needed to prevent pathogenic self-reactivity remains…
Abstract Number: 2684 • ACR Convergence 2025
Multimodal Analysis Revealed Altered Brain Connectivity Patterns and Neuroinflammatory Processes in the Background of Difficult-To-Treat Rheumatoid Arthritis
Lilla Gunkl-Tóth¹, Gergely Orsi², Noémi Császár-Nagy³, Lili Duzsik⁴, Gábor Mátay⁴, Gábor Kumánovics⁵, Gábor Sütő², Krisztina Csókási², Szabolcs Takács⁶, Zoltán Vidnyánszky⁷, József Kun², Krisztina Takács-Lovász², Gellért Karvaly⁸, Róbert Farkas⁸, Anett Pintér⁸, Panna Királyhidi⁸, György Nagy⁸ and Zsuzsanna Helyes², ¹Semmelweis University, Budapest, Budapest, Hungary, ²University of Pécs, Pécs, Hungary, ³National University of Public Services, Budapests, Hungary, ⁴Psychosomatic Outpatient Clinic, Budapest, Hungary, ⁵University of Pecs, Pecs, Hungary, ⁶Károli Gáspár University, Budapest, Hungary, ⁷Brain Imaging Centre, Research Centre for Natural Sciences, Budapest, Hungary, ⁸Semmelweis University, Budapest, Hungary
Background/Purpose: Despite advances in rheumatoid arthritis (RA) treatment, 5–20% of patients experience persistent symptoms, particularly pain, and are classified as difficult-to-treat (D2T). Factors such as…
Abstract Number: 2612 • ACR Convergence 2025
Automated, Artificial Intelligence-supported Sonographic Examination of the Hands for the Detection and Quantification of Arthritis and Osteoarthritis in the Hand and Finger Joints in Outpatient Rheumatology Care
Oliver Sander¹, Lea Ormeloh¹, Laura Grünkewitz¹, Martin Gallmann¹, Benedict Blümel¹, Rishi Adhikari¹, Hasan Acar¹, Gamal Chehab¹, Jörg Distler² and Jutta Richter³, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ²University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ³Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, Düsseldorf, Germany
Background/Purpose: The integration of artificial intelligence (AI) in combination with robotics into clinical diagnostics has the potential to increase precision and efficiency and relieve increasingly…
Abstract Number: 2285 • ACR Convergence 2025
Synovium-on-a-chip – Development of a Humanized Rheumatoid Arthritis Model that Mimics Disease and Patient Biological Heterogeneity
Theresa Wampler Muskardin¹, Ruiqi Chen², Yeji Lee³, Azka Ali³, Andrra Nimoni³, Christele Felix³, Hattie Heiland³, Romy Kallas³, Daniel Ramirez⁴, David Mayman³, Timothy Niewold⁵ and Weiqiang Chen⁶, ¹Hospital for Special Surgery and Weill Cornell Medicine, New York, NY, ²New York University - Tandon School of Engineering, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, New York, New York, ⁶New York University, Tandon School of Engineering, New York, NY
Background/Purpose: In rheumatoid arthritis (RA), reasons for treatment resistance and alternate strategies that would be more effective in treatment-resistant patients remain unknown. Accurate methodology to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].